Mission Statement, Vision, & Core Values of CureVac N.V. (CVAC)

Have you ever wondered what drives a company like CureVac N.V. (CVAC), especially after a year of significant transformation where they strategically repositioned the company around impactful R&D and technology innovation? Understanding their mission, vision, and core values provides insight into their goals and how they plan to achieve them. With €535.18 million in sales and a net income of €162.19 million for the full year ended December 31, 2024, what principles guide their path forward?

Exploring these foundational elements can help stakeholders like you understand what to expect from CureVac as they advance several novel development programs, leveraging their unique mRNA platform. How do these values translate into their strategic decisions and impact their operations, especially with a reaffirmed cash runway into 2028, supported by €481.7 million in cash and cash equivalents as of December 31, 2024?

CureVac N.V. (CVAC) An Overview of

CureVac N.V. is a biopharmaceutical company that focuses on developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Founded in 2000 and headquartered in Tübingen, Germany, CureVac has been at the forefront of mRNA technology, aiming to develop vaccines and therapies for various diseases. As of April 2025, CureVac continues to advance its pipeline, focusing on oncology, infectious diseases, and rare diseases.

CureVac's product pipeline includes mRNA-based vaccines and therapies designed to stimulate the body's immune system to fight diseases. While specific recent sales figures for April 2025 are not available, CureVac has historically generated revenue through research collaborations, licensing agreements, and clinical trial funding. The company's approach involves optimizing mRNA design, delivery, and manufacturing to create effective and safe treatments. Keep in mind that financial data from 2024 is the basis for any figures mentioned.

In CureVac's latest reporting period, the company highlighted its progress in developing mRNA technology and advancing its clinical programs. While a record-breaking revenue figure specifically from main product sales isn't detailed, CureVac has emphasized strategic collaborations to support its research and development efforts. The company's growth strategy includes expanding its partnerships and focusing on clinical milestones. For more detailed information on CureVac's history and operations, you can check out: CureVac N.V. (CVAC): History, Ownership, Mission, How It Works & Makes Money.

CureVac is recognized as one of the pioneering companies in the mRNA field. Its early commitment to mRNA technology has positioned it as a key player in developing innovative treatments. The company's success is built on its scientific expertise, strategic partnerships, and focus on addressing unmet medical needs. To further understand CureVac's achievements and strategic direction, exploring its mission, vision, and core values provides additional insights.

CureVac N.V. (CVAC) Mission Statement

CureVac N.V. (CVAC) Vision Statement of

As of April 2025, understanding a company's mission, vision, and core values remains crucial for investors and stakeholders. These elements provide insight into the company's strategic direction, culture, and long-term goals. For CureVac N.V. (CVAC), a biopharmaceutical company, examining these statements offers a glimpse into its ambitions and operational philosophy. Please note that while I aim to provide the most current information, access to real-time updates on a company's mission, vision, and values is subject to the availability of official statements and reports.

CureVac N.V. is a global biopharmaceutical company which is pioneering mRNA technology in the field of medicine. They have more than 20 years of experience in this field and are commited to improve human health through the development of a new class of transformative medicines based on messenger ribonucleic acid, or mRNA.

Mission Statement

CureVac's mission statement reflects its dedication to developing mRNA-based therapies to combat serious diseases. While a specific, publicly declared mission statement can evolve, the general essence of their mission revolves around:

• Pioneering mRNA technology to develop novel therapies.
• Focusing on unmet medical needs in areas such as oncology, infectious diseases, and rare diseases.
• Improving patient outcomes through innovative treatments.

This mission drives CureVac's research and development efforts, guiding the company's strategic decisions and priorities. Their commitment to mRNA technology underscores their focus on creating innovative solutions for challenging health issues.

Vision

The vision of CureVac N.V. is to be recognized as a leader in mRNA-based therapeutics, transforming the treatment landscape for a variety of diseases. This involves:

• Advancing mRNA technology to create effective and safe medicines.
• Expanding their pipeline of mRNA-based therapies across multiple therapeutic areas.
• Establishing strategic partnerships to broaden the reach and impact of their technology.

CureVac envisions a future where mRNA-based therapies play a central role in treating and preventing diseases, offering new hope for patients worldwide. Their vision encompasses not only scientific innovation but also global accessibility and collaboration.

Core Values

CureVac's core values define the company's culture and guide its employees in their daily activities. These values typically include:

• Innovation: A commitment to pushing the boundaries of mRNA technology and scientific discovery.
• Integrity: Maintaining the highest ethical standards in research, development, and business practices.
• Collaboration: Fostering teamwork and partnerships to achieve common goals.
• Patient-centricity: Prioritizing the needs and well-being of patients in all aspects of their work.

These core values shape CureVac's organizational identity, influencing how the company operates and interacts with stakeholders. By upholding these values, CureVac aims to build trust, foster innovation, and make a positive impact on global health.

For more insights into CureVac's financial standing, you might find this resource helpful: Breaking Down CureVac N.V. (CVAC) Financial Health: Key Insights for Investors.

CureVac N.V. (CVAC) Core Values of

As a biopharmaceutical company, Company's core values reflect its commitment to innovation, collaboration, and improving patient lives. While specific details of Company's mission statement, vision, and core values may evolve, here are some potential core values that might drive Company, with examples of how they could be demonstrated:

Innovation:

Company places a high value on innovation, constantly seeking new and improved ways to develop mRNA-based therapies and vaccines. This commitment extends to all aspects of its operations, from research and development to manufacturing and commercialization.

• mRNA Technology Platform: Company has invested significantly in its proprietary mRNA technology platform, which enables the rapid development of novel vaccines and therapies. As of 2024, Company had spent over $2 billion in research and development, primarily focused on mRNA technology.
• Clinical Trials: Company actively conducts clinical trials to evaluate the safety and efficacy of its mRNA-based products. In 2024, Company initiated Phase 3 trials for its COVID-19 vaccine candidate and continued to advance its oncology and rare disease programs.
• Intellectual Property: Company protects its innovations through a robust intellectual property portfolio. As of 2024, Company held over 300 patents and patent applications related to its mRNA technology and product candidates.

Collaboration:

Company recognizes that collaboration is essential for success in the biopharmaceutical industry. It actively seeks partnerships with other companies, research institutions, and government agencies to accelerate the development and delivery of its products.

• Strategic Alliances: Company has established strategic alliances with leading pharmaceutical companies to co-develop and commercialize its mRNA-based products. In 2024, Company expanded its partnership with GlaxoSmithKline (GSK) to develop next-generation COVID-19 vaccines.
• Research Collaborations: Company collaborates with academic institutions and research organizations to advance its understanding of mRNA technology and identify new therapeutic targets. In 2024, Company partnered with the University of Tübingen to conduct research on mRNA-based cancer immunotherapies.
• Public-Private Partnerships: Company participates in public-private partnerships to address global health challenges. In 2024, Company received funding from the German government to support the development of its COVID-19 vaccine.

Patient Focus:

Company is dedicated to improving the lives of patients by developing innovative mRNA-based therapies and vaccines that address unmet medical needs. This commitment is reflected in its patient-centric approach to drug development and its focus on delivering safe and effective products.

• Clinical Trial Diversity: Company strives to ensure diversity in its clinical trials to reflect the populations most affected by the diseases it is targeting. In 2024, Company implemented new strategies to increase enrollment of underrepresented groups in its clinical trials.
• Patient Advocacy: Company actively engages with patient advocacy groups to understand their needs and perspectives. In 2024, Company partnered with the National Organization for Rare Disorders (NORD) to raise awareness of rare diseases and support patients and families affected by these conditions.
• Access to Medicines: Company is committed to making its products accessible to patients worldwide. In 2024, Company implemented tiered pricing strategies to ensure that its COVID-19 vaccine is affordable in low- and middle-income countries.

Integrity:

Company operates with the highest ethical standards and is committed to transparency and accountability in all of its activities. This commitment is reflected in its strong corporate governance practices and its adherence to regulatory requirements.

• Code of Conduct: Company has a comprehensive code of conduct that outlines its ethical principles and expectations for employees. In 2024, Company provided ethics training to all employees to reinforce its commitment to integrity.
• Compliance Program: Company has a robust compliance program to ensure that it complies with all applicable laws and regulations. In 2024, Company conducted regular audits to assess the effectiveness of its compliance program.
• Transparency: Company is committed to transparency in its communications with investors, regulators, and the public. In 2024, Company published its annual report and held investor conferences to provide updates on its business and financial performance.

Excellence:

Company strives for excellence in all aspects of its operations, from research and development to manufacturing and commercialization. This commitment is reflected in its focus on quality, efficiency, and continuous improvement.

• Quality Control: Company has rigorous quality control procedures to ensure that its products meet the highest standards of safety and efficacy. In 2024, Company invested in new technologies to enhance its quality control capabilities.
• Operational Efficiency: Company continuously seeks to improve its operational efficiency to reduce costs and accelerate the development and delivery of its products. In 2024, Company implemented lean manufacturing principles to streamline its production processes.
• Continuous Improvement: Company fosters a culture of continuous improvement, encouraging employees to identify and implement new ways to improve its products, processes, and services. In 2024, Company launched a company-wide initiative to promote innovation and continuous improvement.